Clinical trial · Observational
An Observational Study of Blood Management Techniques in Oncology Surgical Treatment
Blood Management Observation in Oncology Surgical Treatment (BOOST)
NCT00264095CI-TRIAL-00014355completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to observe the methods used to manage blood loss in surgical procedures to remove tumors from patients with cancer and to determine if there is a relationship with the need for blood transfusions.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anemia | — | UNRESOLVED | — |
| Blood Loss, Surgical | — | UNRESOLVED | — |
| Neoplasms | Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Oncological surgery | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- 001
- interventionNames
- Procedure: Oncological surgery
Primary outcomes (1)
- measure
- Patients' medical history; tumor stage; type/site of operation; anticipated vs. actual blood loss; hemoglobin/hematocrit values prior to surgery, blood-saving techniques used; number of units and types of blood transfusions up to 24 hours after surgery
- timeFrame
- 24 hours after surgery
Secondary outcomes (1)
- measure
- Frequency of use of different blood-saving techniques for the various types of operations performed from each of the centers participating in the study
- timeFrame
- within 24 hours after surgery
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with a malignant tumor for which surgery is the first treatment * Having an expected blood loss of at least 500 ml (100 teaspoons), and not more than 3000 ml (600 teaspoons) Exclusion Criteria: * Patients with a malignant tumor for which surgery is not the first treatment (i.e. have received chemotherapy first) * Inability to speak, read and write Dutch
References
Publications (0)
Data not yet available
No reference posted for this study.